Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Jaeb Center for Health Research
Sponsor:
Collaborators:
Regeneron Pharmaceuticals
National Eye Institute (NEI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Jaeb Center for Health Research
ClinicalTrials.gov Identifier:
NCT01909791
First received: July 23, 2013
Last updated: December 9, 2016
Last verified: December 2016
  Purpose

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent of 20/32 or worse) were eligible. Eyes that have central-involved DME with "good" visual acuity (20/25 or better) have not been addressed systematically by recent studies for treatment of DME. Baseline cohort characteristics from the Early Treatment Diabetic Retinopathy Study (ETDRS) suggest that a substantial percentage of eyes with central-involved DME may retain good vision. The investigators do not know definitively whether eyes with central-involved DME and good vision do better with anti-VEGF (vascular endothelial growth factor) (e.g. aflibercept) therapy initially, or focal/grid laser treatment or observation initially followed by anti-VEGF only if vision worsens.

The primary objective of the protocol is to compare the % of eyes that have lost at least 5 letters of visual acuity at 2 years compared with baseline mean visual acuity in eyes with central-involved DME and good visual acuity defined as a Snellen equivalent of 20/25 or better (electronic-ETDRS letter score of 79 or better) that receive (1) prompt focal/grid photocoagulation + deferred anti-VEGF, (2) observation + deferred anti-VEGF, or (3) prompt anti-VEGF.

Secondary objectives include:

  • Comparing other visual acuity outcomes between treatment groups, such as the percent of eyes with at least 5, 10 and 15 letter losses in visual acuity from baseline mean visual acuity, percent of eyes with at least 5 letter gain in visual acuity from baseline, mean visual acuity, mean change in visual acuity, adjusted for baseline mean visual acuity
  • For eyes randomized to deferred anti-VEGF, the percentage of eyes needing anti-VEGF treatment
  • Comparing optical coherence tomography (OCT) outcomes, such as the mean change in OCT central subfield (CSF) thickness, adjusted for baseline mean thickness
  • Comparing the number of eyes with PDR at randomization, proportion of eyes avoiding vitreous hemorrhage or panretinal photocoagulation (PRP) or vitrectomy for PDR between treatment groups
  • Comparing safety outcomes between treatment groups
  • Comparing associated treatment and follow-up exam costs between treatment groups

Condition Intervention Phase
Diabetic Macular Edema
Procedure: Prompt Laser
Drug: Prompt aflibercept
Procedure: Deferred laser
Drug: Deferred aflibercept
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity

Resource links provided by NLM:


Further study details as provided by Jaeb Center for Health Research:

Primary Outcome Measures:
  • Percent of eyes that have lost at least 5 letters of visual acuity at 2 years compared with baseline mean visual acuity [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Percent of eyes with at least 5, 10 and 15 letter losses in visual acuity from baseline mean visual acuity [ Time Frame: 1 & 2 years ]
  • Percent of eyes with at least 5 letter gain in visual acuity from baseline mean visual acuity [ Time Frame: 1 & 2 years ]
  • Mean change in visual acuity, adjusted for baseline mean visual acuity [ Time Frame: 1 & 2 years ]
  • Visual acuity area under the curve between baseline and annual visits [ Time Frame: 1 & 2 years ]
  • Mean change in OCT CSF thickness, adjusted for baseline mean thickness [ Time Frame: 1 & 2 years ]
  • Percent of eyes with at least a 1 and 2 log step increase or decrease on OCT CSF thickness [ Time Frame: 1 & 2 years ]
  • Percent of eyes with OCT CSF thickness of <250 µm on Stratus OCT (or spectral domain equivalent) and at least a 10% OCT CSF thickness decrease [ Time Frame: 1 & 2 years ]
  • Number of injections and/or focal/grid photocoagulation sessions performed [ Time Frame: 1 & 2 years ]
  • Number of scheduled and unscheduled visits [ Time Frame: 1 & 2 years ]
  • Percent of eyes with worsening diabetic retinopathy [ Time Frame: 1 & 2 years ]
  • Of eyes with non-proliferative diabetic retinopathy or proliferative diabetic retinopathy (PDR) at randomization, percent with improvement in diabetic retinopathy [ Time Frame: 1 & 2 years ]
  • Of eyes with PDR at randomization, proportion of eyes avoiding vitreous hemorrhage or panretinal photocoagulation (PRP) or vitrectomy for PDR [ Time Frame: 1 & 2 years ]
  • Mean change in low-contrast visual acuity on Electronic Visual Acuity Tester [ Time Frame: 1 & 2 years ]
  • Total cost of follow-up and treatment [ Time Frame: 1 & 2 years ]
  • For eyes randomized to deferred anti-VEGF, the percentage of eyes needing anti-VEGF treatment. [ Time Frame: 1 & 2 years ]

Estimated Enrollment: 702
Study Start Date: October 2013
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prompt Laser + Deferred Aflibercept
Focal/grid laser followed by intravitreal aflibercept if vision worsens
Procedure: Prompt Laser
Focal/grid laser performed at baseline and as needed during follow-up
Other Names:
  • focal/grid photocoagulation
  • laser treatment
Drug: Deferred aflibercept
Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
Other Names:
  • intravitreal anti-VEGF
  • Eylea
Active Comparator: Observation + Deferred Aflibercept
No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Procedure: Deferred laser
Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Other Names:
  • focal/grid photocoagulation
  • laser treatment
Drug: Deferred aflibercept
Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
Other Names:
  • intravitreal anti-VEGF
  • Eylea
Experimental: Prompt Aflibercept
Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Drug: Prompt aflibercept
Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Other Names:
  • intravitreal anti-VEGF
  • Eylea
Procedure: Deferred laser
Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Other Names:
  • focal/grid photocoagulation
  • laser treatment

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >= 18 years
  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    Any one of the following will be considered to be sufficient evidence that diabetes is present:

    1. Current regular use of insulin for the treatment of diabetes
    2. Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
    3. Documented diabetes by American Diabetes Association (ADA) and/or World Health Organization (WHO) criteria.
  3. Able and willing to provide informed consent.

Meets all of the following ocular criteria in at least the one eye:

  1. Best corrected E-ETDRS visual acuity letter score ≥ 79 (approximate Snellen equivalent 20/25 or better) at two consecutive visits within 1 to 28 days.
  2. On clinical exam, definite retinal thickening due to DME involving the center of the macula.
  3. Diabetic macular edema confirmed on OCT (equivalent to CSF thickness on OCT ≥250 microns on Zeiss Stratus or gender-specific spectral domain OCT equivalent) at two consecutive visits within 1 to 28 days.

    (a) Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality.

  4. The investigator is comfortable with the eye being randomized to any of the three treatment groups (observation, laser, or anti-VEGF initially).

    (a) If focal/grid photocoagulation is contraindicated because all leaking microaneurysms are too close to the fovea or the investigator believes the DME that is present will not benefit from focal/grid photocoagulation, the eye should not be enrolled.

  5. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate OCT and fundus photographs.

Exclusion Criteria:

  1. History of chronic renal failure requiring dialysis or kidney transplant.
  2. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  3. Initiation of intensive insulin treatment (a pump or multiple daily injections) within 4 months prior to randomization or plans to do so in the next 4 months.
  4. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.

    (a) Note: study participants cannot receive another investigational drug while participating in the study.

  5. Known allergy to any component of the study drug.
  6. Blood pressure >180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
  7. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization.

    These drugs should not be used during the study.

  8. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.

    (a) Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

  9. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the 24 months of the study.

Individual has any of the following ocular characteristics:

  1. Macular edema is considered to be due to a cause other than DME.

    a) An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are contributing to the macular edema.

  2. An ocular condition is present such that, in the opinion of the investigator, any visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).
  3. An ocular condition is present (other than DME) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
  4. Cataract is present that, in the opinion of the investigator, may alter visual acuity during the course of the study.
  5. Any history of prior laser or other surgical, intravitreal, or peribulbar treatment for DME (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, or anti-VEGF).
  6. History of topical steroid or nonsteroidal anti-inflammatory drugs (NSAID) treatment within 30 days prior to randomization.
  7. History of intravitreal or peribulbar corticosteroid within 4 months prior to randomization for an ocular condition other than DME.
  8. Any history of or anticipated need for intravitreal anti-VEGF within the next 6 months for an ocular condition other than DME (e.g. choroidal neovascularization, central retinal vein occlusion, PDR).
  9. History of PRP within 4 months prior to randomization or anticipated need for PRP in the 6 months following randomization.
  10. Any history of vitrectomy.
  11. History of major ocular surgery (cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.
  12. History of YAG capsulotomy performed within 2 months prior to randomization.
  13. Aphakia.
  14. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01909791

  Show 104 Study Locations
Sponsors and Collaborators
Jaeb Center for Health Research
Regeneron Pharmaceuticals
National Eye Institute (NEI)
National Institutes of Health (NIH)
Investigators
Study Chair: Carl Baker, MD Paducah Retina Center
Principal Investigator: Adam Glassman, MS Jaeb Center for Health Research
  More Information

Responsible Party: Jaeb Center for Health Research
ClinicalTrials.gov Identifier: NCT01909791     History of Changes
Other Study ID Numbers: DRCR.net Protocol V
EY14231 ( Other Grant/Funding Number: National Eye Institute )
EY23207 ( Other Grant/Funding Number: National Eye Institute )
EY18817 ( Other Grant/Funding Number: National Eye Institute )
Study First Received: July 23, 2013
Last Updated: December 9, 2016

Keywords provided by Jaeb Center for Health Research:
Diabetic Macular Edema
anti-vascular endothelial growth factor

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 27, 2017